Eli Lilly And Co vs iShares Silver Trust — how do they compare? Eli Lilly And Co trades at $1,221.73 (market cap $1.08T), while iShares Silver Trust trades at $59.12. The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals.
| LLY | SLV | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | — |
52-Week High | $1.24K | $105.57 |
52-Week Low | $639.43 | $33.89 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
SLV trades at $59.45, showing minimal daily movement with a 0.07% gain. The technical outlook is bullish with strong moving average support, though RSI levels suggest potential overbought conditions near-term. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, with the metal recovering from earlier 2026 declines.
Silver's investment case remains compelling due to structural supply constraints and growing industrial demand, particularly from technology sectors. Key risks include Federal Reserve policy uncertainty and dollar strength, while technical resistance near $60 presents immediate price challenges. The metal's volatility requires careful position sizing despite positive long-term fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →